https://www.live-feeds.com/feed/people-switching-to-novo-s-wegovy-pill-from-obesity-injections-kept-losing-weight-in-real-world-studyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/people-switching-to-novo-s-wegovy-pill-from-obesity-injections-kept-losing-weight-in-real-world-studyhttps://www.live-feeds.com/feed/people-switching-to-novo-s-wegovy-pill-from-obesity-injections-kept-losing-weight-in-real-world-study#u96028Sat, 03 Oct 2026 07:50:49 +0000Adults with overweight or obesity who transitioned from injectable GLP-1 weight-loss medications to Novo Nordisk's once-daily oral semaglutide pill continued to drop pounds in a real-world study. Patients who remained on the Wegovy pill for three months achieved an average weight loss of 4.1%, equivalent to 8.8 pounds from an average starting weight of 221.6 pounds. The data indicates patients may not require weekly injections indefinitely and can transition to more convenient oral therapies without halting their progress.Why it mattersThe findings stem from the OCTANE study, which analyz